Back to Journals » OncoTargets and Therapy » Volume 10

The coexpression of EphB4 and EphrinB2 is associated with poor prognosis in HER2-positive breast cancer

Authors Li X, Song C, Huang G, Sun S, Qiao J, Zhao J, Zhao Z, Li M

Received 20 January 2017

Accepted for publication 22 February 2017

Published 21 March 2017 Volume 2017:10 Pages 1735—1742

DOI https://doi.org/10.2147/OTT.S132806

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Akshita Wason

Peer reviewer comments 2

Editor who approved publication: Dr William Cho

This paper has been Retracted 
 
Xuelu Li,1,* Chen Song,2,* Gena Huang,2 Siwen Sun,2 Jingjing Qiao,2 Jinbo Zhao,2 Zuowei Zhao,1 Man Li2

1Department of Breast Surgery, 2Department of Oncology, The Second Hospital of Dalian Medical University, Dalian, People’s Republic of China

*These authors contributed equally to this work

Objective: HER2 overexpression is associated with aggressive phenotypes in breast cancer, including increased tumor proliferation, greater invasiveness, and reduced overall survival. The overall response rate to HER2-targeted therapies remains <30%. There is an urgent need for the identification of efficient markers to predict patients with a poor prognosis. This study was designed to investigate the correlation between EphB4 and EphrinB2 expression and the clinicopathological characteristics of HER2-positive breast cancer.
Materials and methods:
A total of 111 primary HER2-positive breast cancer patients were enrolled in this study (diagnosed since December 2005 to November 2010 from the Second Hospital of Dalian Medical University). The protein expression of EphB4 and EphrinB2 was examined by immunohistochemistry using paraffin-embedded tumor tissues.
Results: There was a significant correlation between EphB4 and EphrinB2 expression (P=0.013, r=0.255). Kaplan–Meier analysis showed that the prognosis of patients with a high expression of both EphB4 and EphrinB2 was significantly worse than the prognosis of patients with either EphB4 or EphrinB2 expression and patients with negative expression (hazard ratio [HR] =1.935, P=0.0224). However, high expression of EphB4 or EphrinB2 alone was not an independent prognostic factor to predict worse overall survival. To summarize, HER2-positive breast cancer patients with overexpression of both EphB4 and EphrinB2 were associated with the worst prognosis.
Conclusion: High expression of EphB4 and EphrinB2 correlated with poor overall survival, which can serve as an independent prognostic indicator in primary HER2-positive breast cancer patients.

Keywords: breast carcinoma, EphB4, EphrinB2, prognosis

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]